Loading
Metastatic Beast Cancer · Observational Study
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active observational study registered to develop and validate a new EORTC quality-of-life module specifically for metastatic breast cancer patients. No results are reported in this registry record. The study aims to address an identified gap in HRQOL measurement tools by conducting patient interviews across European centres to guide questionnaire design; clinical utility and validity remain to be established.
Observational. Metastatic Beast Cancer; Female; age from 18 Years. Intervention: Development of a new EORTC metastatic breast cancer module questionnaire to assess HRQOL, guided by patient interviews and designed for use with the EORTC QLQ-C30.. n = 568. 22 sites across 14 countries.
This is an active observational study registered to develop and validate a new EORTC quality-of-life module specifically for metastatic breast cancer patients. No results are reported in this registry record. The study aims to address an identified gap in HRQOL measurement tools by conducting patient interviews across European centres to guide questionnaire design; clinical utility and validity remain to be established.
Observational design and patient-interview methodology preclude inference of clinical efficacy or safety.
This is a tool-development study, not an efficacy trial. Clinicians should note that a new HRQOL questionnaire is under development; clinical adoption will depend on validation results, which are not yet available in this registry record.
This is an active observational registry record describing an ongoing module development study with no results reported; it is a feasibility and instrument-development project, not an efficacy or safety trial.
As stated by the source record.
Quoted from the source exactly as published.
This is a tool-development study, not an efficacy trial. Clinicians should note that a new HRQOL questionnaire is under development; clinical adoption will depend on validation results, which are not yet available in this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07806266). This is a study registration, not published results. Lead sponsor: University of Leeds. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 568 participants (ESTIMATED). Conditions: Metastatic Beast Cancer. Primary outcome measures: Quality of life of females with metastatic breast cancer , 1 month. Brief summary: The overall aim of this project is to help improve the Health Related Quality of Life (HRQOL) of metastatic breast cancer (MBC) patients. There is currently an urgent and unmet need for specific tools to aid in the evaluation of HRQOL in MBC and this project aims to address these needs by developing a comprehensive EORTC questionnaire for assessing the HRQOL of this group. The new module will be used in conjunction with EORTC QLQ-C30 and will provide better measurement of the quality of life issues experienced by women with MBC. Interviews will be conducted with patients from several centres across Europe, guiding the development process in a patient centred way.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.